The future of IBD treatment.

摘要: Throughout most of the past 50 years, treatment Crohn's disease and ulcerative colitis has been dominated by use agents whose efficacy was defined on an empiric basis. Many these, including especially 5-amino salicylic acid (5-ASA)-based corticosteroids, remain mainstays current even as research is catching up with clinical experience to define mechanistic basis their efficacy. Other agents, also established utility in at least a subset patients, were developed general inferences about pathogenesis. These are exemplified antibiotics (metronidazole) immunosuppressive (azathioprine/6-mercaptopurine, methotrexate, cyclosporine); attention directed assumption likely importance microbial species immunoactivation, respectively. However, rapid progress, if still incomplete understanding pathophysiological mechanisms that play role IBD, transformed development new therapeutic enabling several now available or currently advanced development. It notable each major overall thrusts strategies parallels, may be reasonably viewed partial outgrowth of, dominant areas progress relevant IBD.